US5133956A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Radiolabeled metal-binding protein for the treatment of arthritis
Assignee: Mallinckrodt Inc
•
Filing: 1991-05-30
•
Granted: 1992-07-28
•
Expires: 2011-05-30
Abstract
Abstract Radioactive high molecular weight metal-binding protein compositions and a method for therapeutic radiation treatment including the treatment of rheumatoid arthritis comprising injection of a radioactive high molecular weight metal-binding protein compositions are disclosed.
Inventors
- 👤 Joseph R. Garlich
- 👤 Kenneth McMillan
- 👤 Jaime Simon
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 02:36
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/08; A61K51/088; A61P; A61P19/00; A61P19/02; A61P29/00; C; C07; C07B; C07B59/00; C07B59/008; A61K2121/00
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
67 words
A method for the treatment of rheumatoid arthritis comprising injecting into the synovium of a subject in need of such treatment a therapeutically effective amount of a pharmaceutical composition comprising a metal-binding protein having a molecular weight of approximately greater than 50,000 and a therapeutic radionuclide bound to the protein, wherein the radionuclide is a beta-emitter with a half-life from about 2 hours to about 7 days.
Claim 2
Independent Claim
67 words
A method for the treatment of rheumatoid arthritis comprising injecting into the synovium of a subject in need of such treatment a therapeutically effective amount of a pharmaceutical composition comprising a metal-binding protein having a molecular weight of approximately greater than 50,000 and a therapeutic radionuclide bound to the protein, wherein the radionuclide is a beta-emitter with a half-life from about 2 hours to about 7 days.
Claim 3
Independent Claim
75 words
A method for the treatment of rheumatoid arthritis comprising injecting into the synovium of a subject in need of such treatment a therapeutically effective amount of a pharmaceutical composition comprising a protein having a molecular weight of approximately greater than 50,000, a bifunctional chelator covalently attached to the protein, and a therapeutic radionuclide chelated to the bifunctional chelator, wherein the radionuclide is a beta-emitter having a half-life of about 2 hours to about 7 days.
Claim 4
Independent Claim
75 words
A method for the treatment of rheumatoid arthritis comprising injecting into the synovium of a subject in need of such treatment a therapeutically effective amount of a pharmaceutical composition comprising a protein having a molecular weight of approximately greater than 50,000, a bifunctional chelator covalently attached to the protein, and a therapeutic radionuclide chelated to the bifunctional chelator, wherein the radionuclide is a beta-emitter having a half-life of about 2 hours to about 7 days.
Claim 5
Dependent Claim
17 words
The method of claim 1, wherein the protein has a molecular weight of approximately greater than 250,000.
Claim 6
Dependent Claim
10 words
The method of claim 3 wherein the protein is ferritin.
Claim 7
Dependent Claim
10 words
The method of claim 2 wherein the protein is transferrin.
Claim 8
Dependent Claim
16 words
The method of claim 2, wherein the bifunctional chelator contains a polyaminocarboxylate or polyaminophosphonate chelating moiety.
Claim 9
Dependent Claim
31 words
The method of claim 6 wherein the bifunctional chelator is selected from the group consisting of 1,3-propanediamine-N-(carboxy-propyl)-N,N',N'-trimethylenephosphonic acid, ethylenediamine-N-(4-aminophenethyl)-N,N',N',-trimethylenephosphonic acid, ethylenediaminetetramethylenephosphonic acid, 1-(carboxy)ethylenediaminetetramethylenephosphonic acid, 1-(4-aminobenzyl)ethylenediaminetetramethylenephosphonic acid, N"-(4-aminophenyl)-dipropylenetriamine-N',N',N'",N'"-tetramethylenephosphonic acid and N"-(4-aminophenethyl)-diethylenetriamine-N'N',N'",N'"-tetramethylenephosphonic acid.
Claim 10
Dependent Claim
17 words
The method of claim 6, wherein the bifunctional chelator contains a cyclic polyaminocarboxylate or polyaminophosphonate chelating moiety.
Claim 11
Dependent Claim
45 words
The method of claim 8, wherein the bifunctional chelator is selected from the group consisting of α-aminophenyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, substituted 1,4,7-tris-carboxymethyl-1,4,7,10-tetraazacyclododecane, 1,4,8,11-tetraazacyclotetra-decane-N,N',N",N'"-tetraacetic acid, 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N',N",N'"-tetraacetic acid, α-[2-(4-aminophenyl)ethyl]-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, α-[2-(4-aminophenyl)ethyl]-1,4,7,10-tetraazacyclododecane-1-acetic-4,7,10-tris(methylacetic acid, α-(4-aminophenyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, α-(5-amino-2-methoxyphenyl)-1,4,7,10-tetraazacylododecnae-1,4,7,10-tetraacetic acid, 1-[2-(4-aminophenyl)ethyl]-1,4,7,10-tetraazacyclododecnae-4,7,10-triacetic acid, 1,4,7,10-tetraazacyclododecane-N,N',N",N'"-tetraacetic acid, 1,4,7,10-tetraazacyclotridecane-N,N'N",N'"-tetraacetic acid, 1,4,8,11-tetraazacyclotetradecane-N,N'N",N'"-tetraacetic acid, 1,5,9,13-tetraazacyclohexadecane-N,N'N",N'"-tetraacetic acid, and 1,4,7,10-tetraazacyclododenace-1,4,7,10-tetramethylenephosphonic acid.
Claim 12
Dependent Claim
12 words
The method of claim 9 wherein the bifunctional chelator is α-aminophenyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid.
Claim 13
Dependent Claim
12 words
The method of claim 9 wherein the bifunctional chelator is α-[2-(4-aminophenyl)ethyl]-1,4,7,10-tetraazacyclododecane-1-acetic-4,7,10-tris(methylacetic acid).
Claim 14
Dependent Claim
17 words
The method of claim 2, wherein the protein has a molecular weight of approximately greater than 250,000.
Claim 15
Dependent Claim
26 words
The method of claim 1, wherein said radionuclide is selected from the group consisting of Ho-166, Sm-153, Re-186, Rh-105, Lu-177, In-115 m, Dy-165, Sc-47 and Re-188.
Claim 16
Dependent Claim
26 words
The method of claim 2, wherein said radionuclide is selected from the group consisting of Ho-166, Sm-153, Re-186, Rh-105, Lu-177, In-115 m, Dy-165, Sc-47 and Re-188.
Claim 17
Dependent Claim
12 words
The method of claim 13, wherein said radionuclide is Sm-153 or Ho-166.
Claim 18
Dependent Claim
12 words
The method of claim 14, wherein said radionuclide is Sm-153 or Ho-166.
References Cited (Backward Citations)
US3663685A
Cited
US4104366A
Cited
US4622420A
Cited
US5021236A
Cited
US4454106A
Cited
US4898724A
Cited
US4897254A
Cited
US5037630A
Cited
US4752464A
Cited
US4849209A
Cited
US4758429A
Cited
US5032678A
Cited
US4906450A
Cited
US4853209A
Cited
US4915932A
Cited
US4889707A
Cited
US5039326A
Cited
US4976950A
Cited
US4882142A
Cited
US4970062A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-07-28 | 1996-01-27 | 1996-07-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-07-28 | 2000-01-27 | 2000-07-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-07-28 | 2004-01-27 | 2004-07-28 | $7700.00 | Window Closed / Lapsed |